These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 2803906)

  • 1. Late recurrence of Graves' disease.
    Lewis NP
    Br J Clin Pract; 1989 Feb; 43(2):82. PubMed ID: 2803906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experience with carbimazole in the drug treatment of the hyperthyroidism of Graves' diseases in Nigerians.
    Modebe O
    East Afr Med J; 1992 Mar; 69(3):153-6. PubMed ID: 1505405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Recurrence of Graves-Basedow disease: the influence of treatment schedule].
    Goñi Iriarte MJ; Forga Llenas L; Iriarte Beroiz A; Apiñániz EA; Rodríguez Erdozain R; Menéndez Torre E
    Med Clin (Barc); 1995 Jan; 104(1):11-4. PubMed ID: 7877347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Propylthiouracil and carbimazole associated-antineutrophil cytoplasmic antibodies (ANCA) in patients with Graves' disease.
    Harper L; Chin L; Daykin J; Allahabadia A; Heward J; Gough SC; Savage CO; Franklyn JA
    Clin Endocrinol (Oxf); 2004 Jun; 60(6):671-5. PubMed ID: 15163328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relapse after short-term antithyroid therapy of Graves' disease.
    Burr WA; Fitzgerald MG; Hoffenberg R
    N Engl J Med; 1979 Jan; 300(4):200. PubMed ID: 581607
    [No Abstract]   [Full Text] [Related]  

  • 6. Prediction of outcome in Graves' disease after carbimazole treatment.
    Weetman AP; Ratanachaiyavong S; Middleton GW; Love W; John R; Owen GM; Darke C; Lazarus JH; Hall R; McGregor AM
    Q J Med; 1986 Apr; 59(228):409-19. PubMed ID: 2875484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experience with carbimazole in the treatment of the hyperthyroidism of Graves' disease in Nigerian patients.
    Modebe O
    Afr J Med Med Sci; 1995 Dec; 24(4):347-51. PubMed ID: 8886149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short-term single daily dose treatment of hyperthyroid Graves' disease.
    Bakker-Tervoort MA; Lütjens A; Monasch E
    Neth J Med; 1985; 28(10):454-6. PubMed ID: 3841191
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment of Graves' disease with the block-replace regimen of antithyroid drugs: the effect of treatment duration and immunogenetic susceptibility on relapse.
    Weetman AP; Pickerill AP; Watson P; Chatterjee VK; Edwards OM
    Q J Med; 1994 Jun; 87(6):337-41. PubMed ID: 7913766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies of autoimmunity in Graves' disease before and after treatment with carbimazole.
    Zosin I; Arcan P; Lungu G; Cotoi A; Opreanu R
    Endocrinologie; 1988; 26(1):49-53. PubMed ID: 3260398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of remission after antithyroid drug treatment in Graves' disease.
    Young ET; Steel NR; Taylor JJ; Stephenson AM; Stratton A; Holcombe M; Kendall-Taylor P
    Q J Med; 1988 Feb; 66(250):175-89. PubMed ID: 2902655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns of change in the early (20-minute) radioiodine uptake during carbimazole treatment for Graves' disease and their relationship to outcome.
    Wilkin TJ; Isles TE; Crooks J; Gunn A; Beck JS
    J Clin Endocrinol Metab; 1981 Jun; 52(6):1067-72. PubMed ID: 6894449
    [No Abstract]   [Full Text] [Related]  

  • 13. Radioiodine therapy compared in patients with toxic nodular or Graves' hyperthyroidism.
    Franklyn JA; Daykin J; Holder R; Sheppard MC
    QJM; 1995 Mar; 88(3):175-80. PubMed ID: 7767667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prognostic value of anti-TSH receptor antibodies in Basedow's disease treated with carbimazole].
    Duprey J; Izembart M; Vallée G; Goupil M
    Ann Med Interne (Paris); 1986; 137(7):555-8. PubMed ID: 3813296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful management of Graves' disease in a patient undergoing regular dialysis therapy.
    McKillop JH; Leung AC; Wilson R
    Arch Intern Med; 1985 Feb; 145(2):337-9. PubMed ID: 3838431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High iodine (substrate) turnover Graves' disease: the intriguing 'rapid responder' variant of thyrotoxicosis.
    Dalan R; Leow MK; Ng DC
    Ann Clin Biochem; 2008 Nov; 45(Pt 6):612-5. PubMed ID: 18941129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Recurrence after thyreostatic treatment of diffuse toxic goiter in relation to iodine intake].
    Lumholtz IB; Poulsen DL; Siersbaek-Nielsen K; Friis T; Rogowski P; Kirkegaard C; Hansen JM
    Ugeskr Laeger; 1976 Jan; 138(2):83-5. PubMed ID: 946133
    [No Abstract]   [Full Text] [Related]  

  • 18. Graves' disease: thyroid function and immunologic activity.
    Gossage AA; Crawley JC; Copping S; Hinge D; Himsworth RL
    J Nucl Med; 1982 Nov; 23(11):973-7. PubMed ID: 6290623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of carbimazole treatment on specific and non-specific immunological parameters in patients with Graves' disease.
    Charreire J; Karsenty G; Bouchard P; Schaison G
    Clin Exp Immunol; 1984 Sep; 57(3):633-8. PubMed ID: 6147216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term carbimazole intake does not affect success rate of radioactive 131Iodine in treatment of Graves' hyperthyroidism.
    El Refaei SM; Shawkat W
    Nucl Med Commun; 2008 Jul; 29(7):642-8. PubMed ID: 18528187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.